National Pension Service Purchases Shares of 280,442 Insmed, Inc. $INSM

National Pension Service acquired a new stake in Insmed, Inc. (NASDAQ:INSM) in the fourth quarter, Holdings Channel reports. The firm acquired 280,442 shares of the biopharmaceutical company’s stock, valued at approximately $48,808,000.

A number of other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in shares of Insmed by 5.7% in the fourth quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock valued at $3,668,127,000 after purchasing an additional 1,140,524 shares in the last quarter. Darwin Global Management Ltd. grew its holdings in shares of Insmed by 5.8% in the third quarter. Darwin Global Management Ltd. now owns 20,457,445 shares of the biopharmaceutical company’s stock valued at $2,897,797,000 after purchasing an additional 1,112,824 shares in the last quarter. Capital International Investors grew its holdings in shares of Insmed by 1.0% in the third quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company’s stock valued at $1,087,830,000 after purchasing an additional 74,994 shares in the last quarter. Artisan Partners Limited Partnership grew its holdings in shares of Insmed by 49.0% in the third quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock valued at $711,076,000 after purchasing an additional 1,623,342 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Insmed by 14.4% in the fourth quarter. Geode Capital Management LLC now owns 4,299,052 shares of the biopharmaceutical company’s stock valued at $751,936,000 after purchasing an additional 539,625 shares in the last quarter.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on INSM. Royal Bank Of Canada dropped their price objective on shares of Insmed from $220.00 to $205.00 and set an “outperform” rating for the company in a report on Friday, May 8th. Stifel Nicolaus lifted their price objective on shares of Insmed from $205.00 to $208.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Guggenheim dropped their price objective on shares of Insmed from $230.00 to $226.00 and set a “buy” rating for the company in a report on Friday, May 8th. Jefferies Financial Group began coverage on shares of Insmed in a report on Monday, March 16th. They issued a “buy” rating and a $228.00 price objective for the company. Finally, Truist Financial dropped their price objective on shares of Insmed from $205.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $210.95.

Insmed Price Performance

Shares of Insmed stock opened at $106.91 on Monday. Insmed, Inc. has a 52-week low of $65.56 and a 52-week high of $212.75. The company has a 50 day moving average of $134.42 and a 200 day moving average of $157.87. The company has a quick ratio of 4.10, a current ratio of 4.47 and a debt-to-equity ratio of 0.80. The company has a market capitalization of $23.17 billion, a P/E ratio of -18.59 and a beta of 0.79.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.14. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The company had revenue of $305.96 million during the quarter, compared to the consensus estimate of $300.81 million. During the same quarter in the previous year, the firm earned ($1.42) earnings per share. The firm’s quarterly revenue was up 229.7% on a year-over-year basis. As a group, research analysts forecast that Insmed, Inc. will post -2.52 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO William Lewis sold 10,699 shares of Insmed stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $143.52, for a total value of $1,535,520.48. Following the completion of the transaction, the chief executive officer owned 301,185 shares in the company, valued at $43,226,071.20. The trade was a 3.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Roger Adsett sold 88,060 shares of Insmed stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the completion of the transaction, the chief operating officer owned 106,810 shares of the company’s stock, valued at $17,584,130.30. This represents a 45.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 156,643 shares of company stock worth $24,513,766 over the last 90 days. 2.10% of the stock is owned by insiders.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.